Visual Abstract | PCSK9 Inhibitor MK 0616
Image Modality: Illustration Table Figure
Description:
Visual Abstract | (PCSK9 inhibitor MK 0616) Efficacy And Safety Of The Oral PCSK9 Inhibitor, MK-0616, A Macrocyclic Peptide, In The Treatment Of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial
Date: March 06, 2023
Clinical Topics: Dyslipidemia, Prevention, Homozygous Familial Hypercholesterolemia, Lipid Metabolism, Novel Agents
Keywords: ACC Annual Scientific Session, ACC23Slides, Visual Abstract, Hypercholesterolemia, PCSK9 protein, human, Proprotein Convertase 9, Hyperlipidemias, Enzyme Inhibitors, Peptides, Secondary Prevention